Project Grant R01AI192615
Award Date 7/23/26
Completion Date 6/30/31
Dollars Obligated $784K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Irvine, CA 92697, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded the University of California Irvine $823,548 on May 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop antimalarial and antibabesial clinical candidates based on leelamine isonitrile (GB-79). The research program will evaluate the biological activity, pharmacological properties, and mechanism of action of GB-79 and its analogues against Plasmodium falciparum and Babesia species, the...
- The National Institute of Allergy and Infectious Diseases awarded the University of California Irvine $667,643 on August 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a malaria intelligence system and mobile decision-support application for malaria prevention and control in Kenya. The project addresses insecticide-resistant mosquito populations and outdoor biting behavior that have emerged from widespread use of long-lasting insecticide-treated...
- The National Institute of Allergy and Infectious Diseases awarded $431,750 to the University of California Irvine on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855, Assistance Listing Project Grant R21AI199644). The award funds development and validation of a hydro-meteorological malaria model designed to improve forecasts of malaria risk in Africa and to inform tailored vector control strategies adapted to varying environmental and epidemiological...
- The National Institute of Allergy and Infectious Diseases awarded The Regents of the University of California, San Francisco $810,125 on June 9, 2026, to evaluate how perennial malaria chemoprevention (PMC) in early childhood affects the development of naturally acquired immunity to Plasmodium falciparum malaria. The award is made under the Allergy and Infectious Diseases Research program (CFDA 93.855). The recipient will conduct a comprehensive analysis of samples already collected from a...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services National Institutes of Health, awarded Purdue University $239,023 on August 21, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop covalent phosphatidylinositol 4-kinase (PI4K) inhibitors targeting malaria parasites. The project executes hit-to-lead optimization of high-priority molecular scaffolds against Plasmodium species that inhibit...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $451,000 to the University of California, San Francisco under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 15, 2025, with completion scheduled for July 31, 2027. This Project Grant supports the development and application of high-resolution phage immunoprecipitation sequencing (PhIP-Seq) arrays designed to comprehensively evaluate antibody responses to...
- The National Institute of Allergy and Infectious Diseases awarded The Regents of the University of California, San Francisco $816,441 on August 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct a longitudinal evaluation of interactions between variable PfEMP1 virulence genes, anti-PfEMP1 antibody repertoires, and outcomes of naturally occurring Plasmodium falciparum infections. The research leverages a cohort of Ugandan children and adults to...
- The National Institute of Allergy and Infectious Diseases awarded The Regents of the University of California, San Francisco $246,000 on May 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to quantify the contribution of malaria infections imported by agricultural populations to transmission dynamics and antimalarial drug resistance spread in Eswatini. The award funds two specific aims: improving case classification using high-resolution genomic data to...
- The National Institute of Allergy and Infectious Diseases awarded the University of California Irvine $141,712 on February 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize a novel histidine phosphotransfer system involved in the virulence of Mycobacterium tuberculosis. The funded research investigates how virulence-associated dikinase (VADK) coordinates metabolism and virulence in MTB by interacting with partner proteins. The work combines...
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Michigan $234,000 on August 14, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop sustainable production and derivatization of premarineosin A, a potent antimalarial compound. The project establishes premarineosin A as a next-generation antimalarial agent by developing metabolic engineering strategies to achieve sustainable production of the compound and...